Forte Biosciences, Inc. (FBRX)

76.94 +0.02 (+0.03%) USD  |  NASDAQ  |  Aug 24, 16:00
76.94 0.00 (0.00%) After-Hours: 20:00
More

Forte Biosciences EPS Diluted (Quarterly) : -0.9808 for June 30, 2026

EPS Diluted (Quarterly) Chart

View EPS Diluted (Quarterly) for FBRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EPS Diluted (Quarterly) Chart
Start Trial

Historical EPS Diluted (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 -0.9808
March 31, 2026 -1.241
December 31, 2025 -1.914
September 30, 2025 -0.9937
June 30, 2025 -0.9578
March 31, 2025 -1.374
December 31, 2024 -1.119
September 30, 2024 -4.542
June 30, 2024 -6.780
March 31, 2024 -4.025
December 31, 2023 -4.040
September 30, 2023 -6.573
June 30, 2023 -10.57
March 31, 2023 -8.037
December 31, 2022 -5.806
September 30, 2022 -4.491
June 30, 2022 -5.140
March 31, 2022 -4.348
December 31, 2021 -5.661
September 30, 2021 -13.61
Date Value
June 30, 2021 -10.68
March 31, 2021 -9.062
December 31, 2020 -8.916
September 30, 2020 -11.37
June 30, 2020 -238.06
March 31, 2020 -24.22
December 31, 2019 -18.55
September 30, 2019 -8.182
June 30, 2019 -7.47
March 31, 2019 -278.05
December 31, 2018 -359.40
September 30, 2018 -7.20
June 30, 2018 -303.75
March 31, 2018 -242.64
December 31, 2017 -206.25
September 30, 2017 -187.50
June 30, 2017 -210.00
March 31, 2017 -1541.25
June 30, 2016 -1371.58
March 31, 2016 -198.75

EPS Diluted (Quarterly) Range, Past 5 Years

View EPS Diluted (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EPS Diluted (Quarterly) Benchmarks

View EPS Diluted (Quarterly) Benchmarks
Start Trial
argenx SE --
ACADIA Pharmaceuticals, Inc. 0.1822
Alnylam Pharmaceuticals, Inc. 1.207
Anika Therapeutics, Inc. 0.2412
Savara, Inc. -0.1587

EPS Diluted (Quarterly) Related Metrics

Net Income (Quarterly) -23.33M
Total Expenses (Quarterly) 23.33M
Enterprise Value 1.377B
Earnings Yield -6.67%
Normalized Earnings Yield -6.667